145 results about "Meter dose inhaler" patented technology

A system and method for accurately and reliably determining and recording the time, date and location where a medication is used, and a system and method for transmitting, collecting, and using that data to improve clinical care, disease management, and public health surveillance. The device allows information concerning drug usage, including the time, date and location of use, to be transmitted to a remote network computer system so that the data can be evaluated to determine current impairment and future risk, and to identify changes in the frequency, timing, or location of medication usage indicative of change in disease control or management, and to examine spatial, temporal or demographic patterns of medication use or absence of use among individuals and groups. In addition, the device may further be configured to transmit signals indicative of its status, condition or other results to the remote network computer system.

Engineered particles are provided may be used for the delivery of a bioactive agent to the respiratory tract of a patient. The particles may be used in the form of dry powders or in the form of stabilized dispersions comprising a nonaqueous continuous phase. In particularly preferred embodiments the particles may be used in conjunction with an inhalation device such as a dry powder inhaler, metered dose inhaler or a nebulizer.

A therapeutic face mask comprises a face-engaging portion and a single connector having a mask-engaging end and a single treatment-receiving end which has a single attachment mounting for detachably sealingly receiving a treatment attachment, such as an oxygen reservoir bag or a nebulizer. A one-way inhalation valve in the connector permits fluid flow from the treatment-receiving end to the mask-engaging end during inhalation and inhibits fluid flow in the other direction. The mask also includes a valve-governed exhalation port and an anti-asphyxia valve assembly configured to permit fluid flow from ambient to the face-engaging portion during inhalation only when inspiratory effort during inhalation exceeds fluid flow to the treatment-receiving end of the connector. Also provided is an oxygen reservoir bag having a neck shaped for removable coupling to a mating connector of a therapeutic face mask. An oxygen reservoir bag may have a metered-dose inhaler port defined in its neck.

A breath actuated metered dose inhaler including a housing, a mouthpiece positioned at one end of the housing, and a mechanical release mechanism positioned at another end of the housing. The release mechanism is triggered by a diaphragm and the inhaler is configured such that the air inhalation pathway is unimpeded by the release mechanism.

A counter for indicating the number of doses left in a canister that is suitable for use in a metered dose inhaler. The counter is affixed to the canister and includes a module for providing an indication of the number of doses left in the canister and a triggering mechanism for updating the indication in response to activation of the inhaler.

A method for delivering two or more active drug substances to the lungs by inhalation from a single pressurized metered dose inhaler product, said inhaler containing a HFA / cosolvent based solution formulation wherein all the active drug substances are fully dissolved in the formulation.

The inhalation therapy assembly and method of use described herein increases the efficiency of metered dose inhalers by allowing delivery of the doses to a collapsible reservoir which can be manually pumped, ensuring that medicants contained therein are properly and completely delivered to the patient. Terminal and proximal valves of the one-way diaphragm type allow flow of the aerosol medicants while preventing improper expulsion. An exhalation valve is adjustable to ensure the patient exhales suitably to permit proper medicant absorption. A conventional metered dosage inhaler having an approved FDA canister provides proper dosage to the patient and is joined to the collapsible reservoir by a connector having a plurality of apertures for receiving the MDI and an accessory T-fitting.

The inhalation therapy assembly and method of use described herein increases the efficiency of metered dose inhalers by allowing delivery of the doses to a collapsible reservoir which can be manually pumped, ensuring that medicants contained therein are properly and completely delivered to the patient. Terminal and proximal valves of the one-way diaphragm type allow flow of the aerosol medicants while preventing improper expulsion. An exhalation valve is adjustable to ensure the patient expires suitably to permit proper medicant absorption.

The present invention provides therapeutic formulations for solutions of DELTA9-tetrahydrocannabinol (DELTA9 THC) to be delivered by metered dose inhalers. The formulations, which use non-CFC propellants, provide a stable aerosol-deliverable source of DELTA9 THC for the treatment of various medical conditions, such as: nausea and vomiting associated with chemotherapy-muscle spasticity; pain; anorexia associated with AIDS wasting syndrome, epilepsy; glaucoma; bronchial asthma; and mood disorders.

The present invention provides therapeutic formulations for solutions of DELTA9-tetrahydrocannabinol (DELTA9 THC) to be delivered by metered dose inhalers. The formulations, which utilize non-CFC propellants, provide a stable aerosol-deliverable source of DELTA9 THC for the treatment of various medical conditions, such as: nausea and vomiting associated with chemotherapy; muscle spasticity; pain; anorexia associated with AIDS wasting syndrome; epilepsy; glaucoma; bronchial asthma; and mood disorders.

A valve, shaped and sized for metered dose inhalers, consisting of a mount, a central body and top plate with peripheral air passages and central opening for medication delivery. A flexible elastic diaphragm closes the air passages and a central wiper seal on the diaphragm isolates the center opening from the air passageway. Pressure on the rim of the central opening of the diaphragm causes it to open the air passages timed with injection of medication through the central opening.

A manually operated metered dose inhaler includes a dose counter chamber including a dose display tape driven by a ratchet wheel which is driven in turn by an actuator pawl actuated by movement of a canister, the tape unwinding from a stock bobbin during use of the inhaler, a rotation regulator being provided for the stock bobbin and including a wavelike engagement surface with concavities which engage against control elements in the form of protrusions on resilient forks of a split pin thereby permitting incremental unwinding of the stock bobbin yet resisting excessive rotation if the inhaler is dropped onto a hard surface.

Containers for incrementally dispensing pressurized contents are described. The containers comprise a vessel suited to contain pressurized contents, a port integral with the vessel and through which pressurized contents contained in the vessel can be released from the vessel, preferably incrementally in approximately equal amounts, and a measuring device disposed in or otherwise associated with the vessel such that the quantity or amount of contents in the vessel can be measured or assessed. The measuring device senses ambient conditions in the vessel and, directly or with other components, indicates, for example, the amount of pressurized contents remaining in the vessel and displaying it to an observer. With appropriate ancillary components, the measuring device also enables the amount of contents actually released from the vessel during a particular actuation to be compared to a theoretical constant. Also, additionally, the devices of the invention may also include time logging capability (alone or in conjunction with the capability to log other data) the actuation of the dispensing valve for comparison to a prescribed method. Accordingly, devices for incrementally dispensing pressurized contents from such containers are also described. Such devices further comprise a metering value for dispensing pressurized contents from the vessel. In preferred embodiments, each actuation of the metering valve results in release of a pre-determined quantity of the vessel contents. For example, in embodiments wherein the pressurized contents comprise a therapeutic composition, the instant devices include improved Metered Dose Inhalers (MDIs) for delivery of predetermined doses of a therapeutic composition to a patient, wherein the MDIs provide for sensing of the amount, for example, of the therapeutic composition remaining in the vessel after each actuation of the metering valve.

The present invention relates to suspension formulations, especially those for delivering a pharmaceutically active agent in aerosol form using a spray or aerosol device, such as a pressurised metered dose inhaler (pMDI). The formulations may be for pulmonary, nasal, buccal or topical administration, but are preferably for pulmonary inhalation.

The invention relates to suspension aerosol formulations which exhibit stable particle sizes, containing mometasone furoate, about 1 to about 10 weight percent ethanol and 1,1,1,2,3,3,3-Heptafluoropropane as the propellant. A surfactant, such as oleic acid, can also be included. These formulations are suitable for use in metered dose inhalers.

Containers for incrementally dispensing pressurized contents are described. The containers comprise a vessel suited to contain pressurized contents, a port integral with the vessel and through which pressurized contents contained in the vessel can be released from the vessel, preferably incrementally in approximately equal amounts, and a measuring device disposed in the vessel. The measuring device senses ambient conditions in the vessel and, directly or with other components, indicates, for example, the amount of pressurized contents remaining in the vessel and displaying it to an observer; methods for comparing the amount of contents actually released from the vessel compared to a theoretical constant; and methods for time logging (alone or in conjunction with the logging of other data) the actuation of the dispensing valve for comparison to a prescribed method. Devices (including metered dose inhalers) for incrementally dispensing pressurized contents from such containers are also described.

A system and method for accurately and reliably determining and recording the time, date and location where a medication is used, and a system and method for transmitting, collecting, and using that data to improve clinical care, disease management, and public health surveillance. The device allows information concerning drug usage, including the time, date and location of use, to be transmitted to a remote network computer system so that the data can be evaluated to determine current impairment and future risk, and to identify changes in the frequency, timing, or location of medication usage indicative of change in disease control or management, and to examine spatial, temporal or demographic patterns of medication use or absence of use among individuals and groups. In addition, the device may further be configured to transmit signals indicative of its status, condition or other results to the remote network computer system.

The present invention relates to a pharmaceutical formulation for use in the administration of a long-acting β2-agonist by inhalation. In particular this invention relates to a chemically stable highly efficient formoterol HFA solution formulation to be administered by pressurised metered dose inhalers (pMDIs) characterized by a deep lung penetration. The invention also relates to methods for the preparation of said formulation and to its use in respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD).

A dose counter is provided for coupling with a metered dose inhaler. The dose counter includes a top cover that has a top forming an observation window. The top cover forms an interior space receiving therein a circuit board and an electrical cell supplying electrical power. The circuit board includes a counting circuit and a display screen that is arranged under the window. As such, in the use of the inhaler, depression of the top cover actuates the inhaler and causes the display screen to display the number of times of actuation so as to allow a user to realize the remaining number of times for use of the inhaler thereby improving safety of medication use.

Engineered particles are provided may be used for the delivery of a bioactive agent to the respiratory tract of a patient. The particles may be used in the form of dry powders or in the form of stabilized dispersions comprising a nonaqueous continuous phase. In particularly preferred embodiments the particles may be used in conjunction with an inhalation device such as a dry powder inhaler, metered dose inhaler or a nebulizer.

The present invention is directed to devices, systems, and methods for monitoring inhaled drug usage to predict when an acute attack or exacerbation of a disease, such as a respiratory disease, is imminent. Instrumented inhalers that use modular designs with standard components are disclosed, as are systems for monitoring the instrumented inhalers. Also disclosed are methods for determining whether or not a patient's inhaled drug usage pattern indicates that an acute attack or disease exacerbation is imminent, and notifying appropriate medical personnel of any usage patterns indicative of an attack or disease exacerbation. If such an attack or exacerbation is imminent, additional therapeutic agents may be dispensed to the patient or other interventions made.

The present invention is directed to devices, systems, and methods for monitoring inhaled drug usage to predict when an acute attack or exacerbation of a disease, such as a respiratory disease, is imminent. Instrumented inhalers that use modular designs with standard components are disclosed, as are systems for monitoring the instrumented inhalers. Also disclosed are methods for determining whether or not a patient's inhaled drug usage pattern indicates that an acute attack or disease exacerbation is imminent, and notifying appropriate medical personnel of any usage patterns indicative of an attack or disease exacerbation. If such an attack or exacerbation is imminent, additional therapeutic agents may be dispensed to the patient or other interventions made.

The present invention relates to a pharmaceutical formulation for use in the administration of a long-acting β2-agonist by inhalation. In particular this invention relates to a chemically stable, highly efficient salmeterol HFA solution formulation to be administered by pressurised metered dose inhalers (pMDIs) characterized by a deep lung penetration. The invention also relates to methods for the preparation of said formulation and to its use in respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD).

The invention relates to the use of pressurised metered dose inhalers (MDIs) having part or all of their internal surfaces consisting of stainless steel, anodised aluminium or lined with an inert organic coating; and to compositions to be delivered with said MDIs.

An insulated cartridge for use in a metered dose system, such as a metered dose inhaler or a topical sprayer, for a pressurized or non-pressurized system, characterized by comprising an inner container surrounded by an outer container, and the inner container and the outer container The space between the walls defines a gap. The gap can be filled with vacuum, air or a material with low thermal conductivity.

The inhalation therapy assembly and method of use described herein increases the efficiency of metered dose inhalers by allowing delivery of the doses to a collapsible reservoir which can be manually pumped, ensuring that medicants contained therein are properly and completely delivered to the patient. Terminal and proximal valves of the one-way diaphragm type allow flow of the aerosol medicants while preventing improper expulsion. An exhalation valve is adjustable to ensure the patient expires suitably to permit proper medicant absorption.

The present invention relates to active substances in particulate form, to methods for preparing them, to formulations containing them and to uses of such substances and formulations. A preferred embodiment is directed to particulate suspensions having improved flocculation behaviour in a suspension vehicle, such as a hydrofluoroalkane propellant used in metered dose inhalers.

An assembly that provides operational information about operation of a spray device, such as a nasal spray pump or metered dose inhaler. A linkage adapted to extend between a mounting assembly, connected to a stationary part of the spray device, and an adapter assembly, connected to a movable part of the spray device, is in operational relationship with a transducer to enable the transducer to indicate a mechanical relationship between the movable and stationary parts of the spray device corresponding to the operation of the spray device. A data collection and processing system may be connected to the transducer for determining information that may be used to program an automated actuation system.

The invention relates to the use of pressurized metered dose inhalers (MDIs) having part or all of their internal surfaces consisting of stainless steel, anodized aluminum or lined with an inert organic coating; and to compositions to be delivered with said MDIs.